The study team compared livers after donation after brain death (DBD) with two degrees of warm ischemia in DCD donors. Animals subjected to 30 minutes of cardiac arrest (DCD-30) developed marked ischemia–reperfusion injury (IRI); animals in the DCD-60 cohort experienced lethal IRI, and consequently no long-term survival groups were established for that arm. Serum transaminases and lactate dehydrogenase rose substantially in DCD graft recipients compared with DBD controls, indicating severe hepatocellular injury that correlated with the duration of donor warm ischemia. The authors therefore used the DCD-30 condition as their primary experimental model to evaluate therapeutic modulation.
Donor animals received intraperitoneal injections one hour before cardiac arrest. The active compound, ISO-1, was given at 20 mg/kg intraperitoneally, prepared in a minimal volume of DMSO and diluted to a final DMSO concentration of 5.2% in 0.9% NaCl. The vehicle group received the same 5.2% DMSO formulation without ISO-1. After induction of the assigned warm ischemia interval, livers were flushed with 60 mL of 4°C HTK solution and stored for three hours of static cold preservation at 4°C before arterialized orthotopic liver transplantation (OLT). Recipients were sacrificed at 1, 3, 24, and 168 hours after reperfusion for endpoint assessments.
The investigators measured AST, ALT, and LDH as biochemical indicators of hepatocellular injury. At early reperfusion time points, donor pre-treatment with ISO-1 produced a significant reduction in AST compared with vehicle (294 ± 63 vs 867 ± 211 IU/L; p = 0.017). The study team reported that ISO-1-treated animals reached transaminase values comparable to DBD controls. Parallel measurements of damage-associated molecular patterns showed reduced systemic DAMP release after ISO-1: serum HMGB-1 was lower (11 ± 2.8 vs 26 ± 6.2 pg/mL; p = 0.045) and circulating MIF concentrations were reduced (45 ± 5.3 vs 144 ± 27.5 ng/mL; p = 0.034) versus vehicle-treated DCD-30 grafts. These biochemical changes were temporally linked to early reperfusion intervals when sterile inflammation is typically most active.
Microcirculatory function in grafts was assessed using an O2C device; portal venous flow was measured with a transit-time perivascular flowmeter. The authors observed improved graft microcirculation at 24 hours after reperfusion in the ISO-1 group compared with vehicle-treated DCD grafts. Measures of portal flow were reported alongside microcirculatory data; however, the manuscript did not present novel hemodynamic interventions beyond the standard measurement techniques. The improvement in microvascular perfusion coexisted with lower serum DAMPs and reduced transaminase release in the ISO-1 cohort.
Histopathologic evaluation used H&E staining and a semiquantitative Suzuki-derived score to quantify congestion, vacuolization, and hepatocellular necrosis (total score: none = 0 through severe >60% = 4). An experienced veterinary pathologist scored slides in a blinded fashion. ISO-1 treatment attenuated histologic injury compared with vehicle. Immunohistochemical analysis for CD163 identified an altered time course of macrophage infiltration in ISO-1-treated grafts; the authors reported differences in the timing and magnitude of CD163+ cell presence, suggesting modulation of early inflammatory cell dynamics. The manuscript includes grouped western blot images for MIF protein expression and provides raw data in supplementary materials.
Surgical procedures and perioperative care were standardized: all arterialized OLTs were performed by the same microsurgeon and anesthesia and perioperative analgesia regimens were consistent. The study team reported no statistically significant between-group differences in anhepatic time (p = 0.08), total surgery time (p = 0.08), or cold ischemia time (p = 0.12), supporting comparability of intraoperative conditions across experimental arms. Sample sizes were determined a priori based on power calculations referenced by the authors, and animals were randomized to groups. The source specified that n = 7 per group per time point were used for serial sampling.
The authors noted high mortality in the DCD-60 cohort, which precluded establishing long-term survival groups for that arm; this limits interpretation of late graft outcomes after very prolonged donor warm ischemia. The manuscript reports that further mechanistic and translational evaluation of ISO-1 in DCD liver transplantation is warranted. The source did not provide clinical dosing guidance, nor did it supply data on chronic graft survival beyond the time points studied for the DCD-30 model. Raw data files and western blot source images were offered as supplementary materials and data are available upon reasonable request to the institutional contact provided in the article.
Limitations explicitly present in the source include the lethal outcome in the DCD-60 arm and the absence of long-term survival data for that cohort; these constraints frame the immediate applicability of the findings and point to specific unanswered questions about durability of protection, optimal timing of MIF inhibition, and mechanisms linking reduced DAMP release to improved microcirculation. The study team recommended targeted mechanistic studies and translational testing to determine whether donor MIF modulation can be adapted safely and effectively for clinical DCD liver transplantation.